08:48:16 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-05-30 Bokslutskommuniké 2024
2024-02-29 Kvartalsrapport 2024-Q3
2023-12-04 Kvartalsrapport 2024-Q2
2023-10-04 Ordinarie utdelning INTEG B 0.00 SEK
2023-09-27 Årsstämma 2024
2023-08-31 Kvartalsrapport 2024-Q1
2023-06-08 Bokslutskommuniké 2023
2023-03-01 Kvartalsrapport 2023-Q3
2022-12-01 Kvartalsrapport 2023-Q2
2022-10-03 Ordinarie utdelning INTEG B 0.00 SEK
2022-09-28 Årsstämma 2023
2022-08-31 Kvartalsrapport 2023-Q1
2022-06-10 Bokslutskommuniké 2022
2022-03-02 Kvartalsrapport 2022-Q3
2021-12-02 Kvartalsrapport 2022-Q2
2021-09-09 Ordinarie utdelning INTEG B 0.00 SEK
2021-09-02 Kvartalsrapport 2022-Q1
2021-05-31 Bokslutskommuniké 2021
2021-03-03 Kvartalsrapport 2021-Q3
2020-12-02 Kvartalsrapport 2021-Q2
2020-09-30 Årsstämma 2021
2020-09-09 Ordinarie utdelning INTEG B 0.00 SEK
2020-08-24 Kvartalsrapport 2021-Q1
2020-06-08 Bokslutskommuniké 2020
2020-04-20 Extra Bolagsstämma 2020
2020-03-02 Kvartalsrapport 2020-Q3
2019-12-02 Kvartalsrapport 2020-Q2
2019-09-30 Årsstämma 2020
2019-09-25 Ordinarie utdelning INTEG B 0.00 SEK
2019-09-02 Kvartalsrapport 2020-Q1
2019-06-10 Bokslutskommuniké 2019
2019-03-04 Kvartalsrapport 2019-Q3
2018-12-17 Kvartalsrapport 2019-Q2
2018-09-25 Ordinarie utdelning INTEG B 0.00 SEK
2018-09-24 Årsstämma 2019
2018-09-24 Kvartalsrapport 2019-Q1
2018-06-25 Bokslutskommuniké 2018
2018-03-26 Kvartalsrapport 2018-Q3
2017-12-18 Kvartalsrapport 2018-Q2
2017-09-25 Årsstämma 2018
2017-09-25 Kvartalsrapport 2018-Q1
2017-06-30 Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Integrum är verksamt inom medicinteknik. Idag utvecklar bolaget system för skelettförankrade proteser baserat på det framtagna OPRA-implantatsystemet, som senare vidaresäljs till sjukhus världen över. Implantatet sätts på patientens ben med hjälp utav titanskruvar och antas förbättra livet för en stor del patienter med amputation. Bolaget grundades 1998 och har sitt huvudkontor i Mölndal.
2022-05-19 18:22:00

Mölndal, Sweden, May 19, 2022 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the Board of Directors has appointed Rickard Brånemark as CEO of the company. Rickard Brånemark has simultaneously resigned as Chairman of the Board.

Dr. Brånemark is the founder and main owner of Integrum AB and was CEO between 1998-2015. He has pioneered studies of titanium implants to anchor limb prostheses for more than 20 years. As the most experienced surgeon in the field, Dr. Brånemark is internationally recognized for his contributions to amputation treatment research and development. He is currently Research Scientist at MIT, Massachusetts, USA. He has been a member of the board since 2009.

The Board of Directors has appointed Rickard Brånemark as CEO on a full-time basis, effective immediately. Simultaneously, Rickard Brånemark resigned as Chairman of the Board, and the Board of Directors appointed Bengt Sjöholm as new Chairman. Bengt Sjöholm has a vast experience from the medtech industry and has served as Board Director since 2019.

Integrum's previous CEO, Maria Elena Lopez, will continue to support the company during the termination period.

"Since I founded this company with my father in 1998, I have been highly engaged in its development. I am an entrepreneur by heart, and as the company now enters an intense phase of strong commercial growth where our efforts to establish our OPRA[TM] Implant System as the new standard of care are starting to pay off, I welcome this opportunity to lead the company and its many talented employees. I want to sincerely thank Maria Elena Lopez for her extraordinary achievements during the last years, not least her strong contributions during the difficult times of the pandemic and the successful process of our adaption to the new MDR regulation", comments Rickard Brånemark.   

"As the healthcare systems now reopen after the Covid-19-pandemic, Integrum can fully focus on growth. We appreciate that Rickard Brånemark has accepted the role as CEO, yet another sign of his long-term commitment to the company. His experience, strong commercial drive, and extensive global network will serve the company and its shareholders well during the next phase of the company's development", comments Bengt Sjöholm, Chairman of the Board.

Rickard Brånemark is currently resident in the United States and the Swedish Companies Registration Office's registration of him as CEO requires that the Swedish Companies Registration Office grant an exemption from the so called residency requirement stated in the Swedish Companies Act (2005:551), meaning that the CEO must be resident in the European Economic Area. In the event that the Swedish Companies Registration Office denies the application for exemption, the Board will consider possible alternative measures in order for Rickard to be appointed.

This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 2022-05-19 18:22 CET.